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CD341 CELL DOSE AND FULL DONOR CHIMERISM AT DAY 1100 IS
ASSOCIATED WITH SURVIVAL IN PATIENTS WHO RECEIVED REDUCED-
INTENSITY CONDITIONING (RIC) WITH FLUDARABINE/MELPHALAN
PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION (HSCT) FOR HEMATOLOGIC MALIGNANCIES
Holtan, S.G., Hogan, W.J., Elliott, M.A., Gastineau, D.A., Call, T.G.,
Ansell, S.A., Inwards, D.J., Johnston, P.B., Lacy, M.Q., Micallef, I.N.,
Porrata, L.F., Tefferi, A., Litzow, M.R. Mayo Clinic Graduate School
of Medicine, Rochester, MN
Nonmyeloablative, reduced-intensity conditioning extends allo-
geneic HSCT as a therapeutic option for elderly or frail patients
with relapsed, refractory, or other high-risk hematologic malignan-
cies. We reviewed the medical records of the first 50 patients (34 M,
16 F) at our institution who underwent fludarabine/melphalan RIC
from 9/00 to 9/07 to determine factors associated with survival. The
median age at transplant was 53.5 years (range 20–67 years). Most
patients received HSCT for myeloid malignancies (18 AML, 11
MDS, 8 NHL, 7 MM, 2 each CML and CLL, and 1 each AMM
and HL), were in remission at transplant (16 in CR, 9 in PR, 13 re-
lapsed/refractory, and 12 untreated), received stem cells from
a matched related versus unrelated donor (37 vs. 13 pts), and were
a full 6/6 for sibling donors or 10/10 antigenmatch for URD (46 ver-
sus 4 patients with a single antigen mismatch). Half (25 pts) had re-
ceived prior HSCT, and 3 had prior chemotherapy for solid tumors.
28% of patients experienced grade 3–4 acute GVHD, and 46% ex-
perienced chronic GVHD (38% extensive). 26 of 50 pts have died,
5 from relapsed disease. Only one of the deaths before day 1100
was due to relapsed disease, and treatment-related mortality
(TRM) at day1100 was 26% (13 pts). 24 patients (48%) are alive af-
ter a median of 24 months of follow up. Factors associated with sur-
vival on univariate analysis included CD341 cell dose greater than
the median of 5.5 106/L (p5 0.0463), day1100 disease remission
status, (p\0.0001), day 1100 chimerism status (p\0.0001), any
chronic GVHD (p 5 0.0005), and favorable/standard versus poor
risk karyotype for myeloid malignancies (p 5 0.0149). On multivar-
iate analysis, CD34 cell dose greater than 5.5 106/L (RR 0.19, 95%
CI 0.0389 – 0.7222, p 5 0.0136) and full donor chimerism at day
1100 (RR 0.05, 95% CI 0.0099 – 0.2327, p 5 0.0002) remained
an independent prognostic factors. Achievement of full donor chi-
merism was not related to CD34 cell dose (p 5 0.46). In our series,
achievement of full donor chimerism at day 1100 is associated with
70% 2 year survival, a favorable outcome in this high risk group of
patients. While the infused CD34 cell dose can occasionally be a
modifiable variable, whether any other host and/or graft
factors could be modified to promote the establishment of full chi-
merism and improve survival remains largely unknown and merits
confirmation in larger series.286
CLINICOPATHOLOGICAL MANIFESTATIONS AND TREATMENT OF INTES-
TINAL TRANSPLANT-ASSOCIATED MICROANGIOPATHY (I-TAM)
Inamoto, Y.1, Ito, M.2, Suzuki, R.3, Nishida, T.4, Iida, H.5, Kohno, A.6,
Sawa, M.7, Murata, M.1, Nishiwaki, S.1, Naoe, T.2, Fujino, M.6,
Morishita, Y.2, Hirabayashi, N.4, Kodera, Y.4, Miyamura, K.4 1Nagoya
University Graduate School of Medicine, Nagoya, Aichi, Japan; 2Japanese
Red Cross Nagoya First Hospital, Nagoya, Aichi, Japan; 3Nagoya Univer-
sity School ofMedicine, Nagoya, Aichi, Japan; 4 Japanese Red Cross Nagoya
First Hospital, Nagoya, Aichi, Japan; 5Meitetsu Hospital, Nagoya, Aichi,
Japan; 6Konan Kosei Hospital, Konan, Aichi, Japan; 7Anjo Kosei Hospital,
Anjo, Aichi, Japan
Background: Severe diarrhea is a life-threatening complication
after allogeneic hematopoietic stem-cell transplantation. Graft-
versus-host disease (GVHD) has been thought as its major cause,
but diarrhea is often refractory to treatment even after the resolution
of skin GVHD. We previously reported that intestinal transplant-
associated microangiopathy (i-TAM) complicated such patients.
To clarify more detailed clinicopathological manifestations and
treatment of i-TAM, we conducted a retrospective multicenter
study.
Design andMethods:From1997 to 2006, 87 of 886 patients with
diarrhea after transplantation received colonoscopic biopsy. I-TAM,GVHD and cytomegalovirus colitis were distinguished histopatho-
logically.
Results: The median duration from transplantation to the onset
of diarrhea was 32 days (range: 9–130 days), and that from the on-
set of diarrhea to biopsy was 12 days (range: 0–74 days). The me-
dian maximal amount of diarrhea was 2 L/day (range: 130–5600
ml/day). Histopathological diagnosis included i-TAM (n 5 80),
GVHD (n 5 26), cytomegalovirus colitis (n 5 17) and non-specific
(n 5 2) with overlapping. Among 80 patients with i-TAM, abdom-
inal pain was a major symptom, and only 10 patients fulfilled the
proposed criteria for systemic TAM. Nonrelapse mortality
(NRM) among patients without resolution of diarrhea was 72%
and i-TAM comprised 57% of NRM. NRM was 25% among pa-
tients without intensified immunosuppression, but was 52%, 79%
and 100% among those with intensified immunosuppression be-
fore diarrhea, after diarrhea, and before and after diarrhea, respec-
tively.
Conclusions: I-TAM is a major complication presenting massive
refractory diarrhea and abdominal pain, which causes NRM. Avoid-
ing intensified immunosuppression which damages vascular endo-
thelium may improve transplant outcome, and further prospective
trials are warranted.287
CONDITIONING WITH CLOFARABINE AND BUSULFAN X 4 (CLOBU4) FOR
NON-REMISSION HEMATOLOGIC MALIGNANCIES INCLUDING AML IS
WELL TOLERATED, FACILITATES SECURE ENGRAFTMENT, AND EX-
HIBITS SIGNIFICANT ANTI-TUMOR ACTIVITY
Magenau, J.1,2, Pawarode, A.1, Buck, T.1, Jones, D.1, Kato, K.1,
Frame, D.1, Kujawski, L.2, Erba, H.P.2, Khaled, Y.1, Peres, E.M.1,
Krijanovski, O.I.1, Reddy, P.1, Kitko, C.1, Choi, S.1, Yanik, G.1,
Braun, T.1, Ferrara, J.L.M.1, Levine, J.E.1, Mineishi, S.1 1University
of Michigan, Ann Arbor, MI; 2University of Michigan, Ann Arbor, MI
Background: Combining fludarabine with myeloablative doses
of busulfan (FluBu4) has shown reduced toxicity when compared
to other myeloablative regimens. We replaced fludarabine with
clofarabine, a purine antimetabolite with potent anti-leukemia
properties, in a phase I/II trial of Clofarabine-Busulfan  4
(CloBu4) in pts with refractory hematologic malignancies not in re-
mission at the time of allogeneic hematopoetic stem cell transplant
(HSCT).
Methods: Busulfan was administered once daily at 3.2 mg/kg IV x
4d (days -5 to -2) and clofarabine once daily at 20, 30 or 40mg/m2 IV
x 5d (days -6 to -2). Pts received dexamethasone 12mg IV on the days
of clofarabine. GVHD prophylaxis was tacrolimus/MMF in all but
one patient.
Results: Of 23 pts enrolled, 22 were evaluable for toxicity/en-
graftment, and 21 for response ($ day 30). One patient withdrew
prior to conditioning. Diseases are AML (n 5 14), ALL (n 5 3),
CLL (n 5 2), NHL (n 5 2), and MM (n 5 1). Six pts received prior
stem cell transplantation (2 auto; 4 allo). Clofarabine dose levels
were: 20 mg/m2 (n 5 6), 30 mg/m2 (n 5 15) and 40 mg/m2 (n 5
1). The median age was 53 years (range 13–68). Donors were related
(n5 10) or unrelated volunteers (n5 12). CloBu4 was generally well
tolerated. Grade 3–4 toxicities attributable to the conditioning reg-
imen included: transient liver enzyme abnormalities (9/22), transient
hypoxia (5/22), hypertension (2/22), and seizure (1/22). Hypersensi-
tivity to clofarabine occurred in one patient however subsequent
doses were tolerated with additional dexamethasone. Also noted
were ascites (n 5 2) in the first post-transplant month with liver bi-
opsy findings in one pt suggestive of veno-occlusive disease (VOD).
Both patients were at increased risk for hepatic complications (pre-
transplant liver damage, splenomegaly from preceding myelofibro-
sis). To date, all patients have successfully engrafted. Acute
GVHD ($ grade 2) developed in 2/21 pts (10%) and was fatal in
one case. Thusfar, 16/21(76%) pts achieved CR on day 30 (11/13
pts with AML) and the 1 year survival is 68% with a median follow
up of 6 months.
Conclusion: Early results show clofarabine is well tolerated when
administered with full dose busulfan in high risk HSCT pts. All pts
engrafted rapidly, and this combination shows promising anti-tumor
activity in very high risk hematologic malignancies. The trial con-
tinues to accrue patients and updated results will be presented at
the meeting.
